GO:0051428 peptide hormone receptor binding

GO:0051428 peptide hormone receptor binding is a molecular function term that describes the binding of a peptide hormone to its specific receptor. Peptide hormones are signaling molecules secreted by endocrine cells that travel through the bloodstream to act on distant target cells. Their receptors are typically integral membrane proteins, often G protein-coupled receptors (GPCRs), which transduce the binding event into intracellular signals. This binding event is the first and essential step in a cascade of cellular responses that regulate growth, metabolism, reproduction, and stress responses. Understanding the molecular details of peptide hormone receptor binding is therefore fundamental to both basic biology and therapeutic development. Research into peptide hormone receptor binding has revealed that these interactions are not simple lock-and-key events. Agonist binding often involves multiple contact points and induces conformational changes in the receptor that lead to activation. For example, the binding of H2 relaxin to its receptor RXFP1 involves a complex mode of interaction that includes both the peptide's A-chain and B-chain. Moreover, peptide hormone receptors can form complexes with coreceptors or accessory proteins that modulate ligand binding and signaling specificity. These complexities make the study of peptide hormone receptor binding a rich field for structural and pharmacological investigation. From a clinical perspective, peptide hormone receptor binding is a validated drug target. Many approved drugs are peptide agonists or antagonists that act by mimicking or blocking natural hormone-receptor interactions. Additionally, aberrant peptide hormone receptor binding can contribute to disease pathogenesis, such as in cancer or reproductive disorders. Therefore, tools and methods to precisely characterize these binding events are in high demand. This article provides a comprehensive overview of GO:0051428, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and research methodologies, with a focus on CRISPR-based models and services offered by EDITGENE.

According to the Gene Ontology, GO:0051428 peptide hormone receptor binding is defined as the molecular function of binding to a receptor for a peptide hormone. In other words, it describes the interaction between a peptide hormone ligand and its specific receptor protein. This term is used to annotate gene products that physically interact with peptide hormone receptors, including the hormones themselves, synthetic analogs, or accessory proteins that modulate the binding. The synonym polypeptide hormone receptor binding is also used. This function is distinct from receptor activity itself (which would be GO:0004872) because it focuses on the binding event from the ligand or modulator perspective, rather than the signal transduction capability of the receptor.

Peptide hormone receptor binding is a fundamental molecular event that underlies intercellular communication in multicellular organisms. It is the first step in a wide range of physiological processes, including growth, metabolism, reproduction, and stress responses. Because of its central role, this function is a major focus in drug discovery, with many therapeutics designed to either mimic or block peptide hormone-receptor interactions. Moreover, understanding the structural and dynamic aspects of binding can inform the design of more effective and selective drugs. In research, the ability to measure and manipulate peptide hormone receptor binding is essential for dissecting signaling pathways and for developing models of endocrine diseases.

The following genes encode peptide hormones and their receptors that are directly involved in GO:0051428 peptide hormone receptor binding, as supported by published literature.

The binding of peptide hormones to their receptors is regulated at multiple levels. Receptor expression levels can be modulated by transcriptional and post-transcriptional mechanisms, affecting the number of available binding sites. Ligand availability is controlled by secretion, degradation, and binding proteins. Additionally, receptor desensitization, internalization, and recycling can rapidly alter binding capacity. Allosteric modulators and coreceptors can also influence binding affinity and efficacy. For example, the binding of H2 relaxin to RXFP1 is modulated by the receptor's complex activation mechanism, which may involve multiple binding sites and conformational states. These regulatory mechanisms ensure that hormone signaling is tightly controlled in space and time.

Aberrant peptide hormone receptor binding can drive cancer progression. For instance, overexpression or mutation of peptide hormone receptors such as GLP1R, GCGR, or RXFP1 can lead to constitutive signaling that promotes cell proliferation and survival. In addition, peptide hormones like insulin and insulin-like growth factors can stimulate cancer cell growth through their receptors. Targeting these binding interactions with antagonists or antibodies is a therapeutic strategy in oncology.

Peptide hormone receptor binding is critical for normal reproductive function. Mutations in GNRHR, LHCGR, or FSHR can cause hypogonadism, infertility, or ovarian dysgenesis. The binding of anti-Mullerian hormone (AMH) to its receptor AMHR2 regulates follicle recruitment; a novel AMH receptor 2 binding peptide has been shown to prevent chemotherapy-related ovarian follicle loss in a mouse model. This highlights the therapeutic potential of modulating peptide hormone receptor binding in fertility preservation.

Dysregulation of peptide hormone receptor binding underlies metabolic disorders such as type 2 diabetes and obesity. Insulin binding to INSR is impaired in insulin resistance, while GLP-1 receptor binding is the target of incretin mimetics used to treat diabetes. Similarly, mutations in AVPR2 that impair vasopressin binding cause nephrogenic diabetes insipidus. Understanding the molecular details of these binding events is essential for developing effective therapies.

NMR spectroscopy is a powerful technique for characterizing peptide hormone/receptor interactions in solution, providing atomic-level information on binding interfaces and dynamics. Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can measure binding kinetics and thermodynamics. These methods are often used with purified receptor ectodomains and synthetic peptides.

Radioligand binding assays using iodinated peptide hormones are classic methods to measure receptor affinity and density. Fluorescence-based assays, such as time-resolved FRET, allow real-time monitoring of binding in live cells. These assays can be adapted for high-throughput screening of drug candidates.

CRISPR-Cas9 genome editing enables the creation of knockout, knock-in, or point-mutation cell lines to study the function of specific genes in peptide hormone receptor binding. For example, knocking out a candidate coreceptor can reveal its necessity for binding. Tagged knock-in of receptors allows visualization and pull-down of binding complexes.

A rapid method for identifying peptide-receptor-coreceptor complexes in protoplasts has been developed. This technique involves expressing the receptor and candidate coreceptors in plant protoplasts and detecting binding using fluorescently labeled ligands. It enables high-throughput screening of coreceptor candidates and can be adapted for mammalian systems.

Researchers studying peptide hormone receptor binding-related genes often need to determine whether a candidate gene is causally involved in the binding event or whether it modulates the interaction. This requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides comprehensive services to generate such models and to support downstream functional studies.

GO:0051428 peptide hormone receptor binding is a fundamental molecular function that governs endocrine signaling and has broad implications for human health and disease. Understanding the structural, biochemical, and genetic basis of this interaction is essential for developing new therapies. With the advent of CRISPR genome editing, researchers can now precisely manipulate genes involved in this function to uncover causal mechanisms. EDITGENE offers a comprehensive suite of services to facilitate such studies, from custom cell model generation to high-throughput screening and bioinformatics analysis.